Clinical Outcome | Baseline Visit | 6 and 12 Month Visits | Effect Estimate |
---|---|---|---|
Continuous Outcomes | Mean + SD | Mean + SD | Dif. in mean change (95% CI) |
Standardized ACT scorec, d |  |  | 10% (− 12, 39%) |
  Intervention | 83.4 + 9.53 | 85.0 + 9.63 |  |
  Control | 81.3 + 11.3 | 82.9 + 12.2 |  |
  uLTE4 (ng/mg)d |  |  | −10% (−20, 1%) |
  Intervention | 1.35 + 1.45 | 1.26 + 1.50 |  |
  Control | 1.40 + 1.52 | 1.40 + 1.44 |  |
FeNO (ppb)d |  |  | 4% (−20, 34%) |
  Intervention | 15.5 + 2.26 | 15.8 + 1.11 |  |
  Control | 13.3 + 2.52 | 13.3 + 1.12 |  |
 |  |  | Dif. in mean (95% CI) |
Unscheduled clinical utilization, visits |  |  | −0.14 (−0.48, 0.20) |
  Intervention | – | 0.25 + 0.81 |  |
  Control | – | 0.38 + 0.65 |  |
Steroid prescriptions, n |  |  | −0.12 (− 0.70, 0.45) |
  Intervention | – | 0.53 + 1.18 |  |
  Control | – | 0.74 + 1.21 |  |
Dichotomous Outcomes | % | % | IRR (95% CI) |
C-ACT or ACT score < 19a, yes |  |  | 0.45 (0.21, 0.97) |
  Intervention | 15.8 | 8.3 |  |
  Control | 32.4 | 20.0 |  |
Symptoms in past 2 wk., yes | Â | Â | 0.77 (0.52, 1.13) |
  Intervention | 55.3 | 38.9 |  |
  Control | 59.5 | 47.9 |  |
ULTE4 (ng/mg)Â >Â medianb, yes | Â | Â | 0.77 (0.53, 1.11) |
  Intervention | 46.0 | 37.5 |  |
  Control | 54.3 | 51.6 |  |
Elevated FeNO, yes | Â | Â | 0.86 (0.49, 1.50) |
  Intervention | 43.2 | 31.0 |  |
  Control | 27.0 | 31.3 |  |
Discrete Outcome | Mean (SD) | Mean (SD) | IRR (95% CI) |
Symptoms in past 2 wk., days | Â | Â | 0.63 (0.35, 1.11) |
  Intervention | 1.63 + 1.88 | 1.43 + 2.53 |  |
  Control | 2.03 + 2.90 | 2.04 + 3.54 |  |